Elutia (ELUT) vs ImageneBio (IMA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Elutia (ELUT) has outperformed ImageneBio (IMA) over the past year, gaining 52.6% versus a loss of 44.9%. Over five years, ELUT leads with a -82.8% price change compared with -97.9% for IMA. ImageneBio is the larger company by market cap ($48.8 million vs $40.0 million), about 1.2 times the size, while Elutia is growing revenue faster (-15.0% vs -77.1%).
Elutia converts more of its revenue into profit, with a net margin of 434.2% versus -5668.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELUT | IMA |
|---|---|---|
| Share price | $0.9001 | $3.92 |
| Market cap | $39.96M | $48.83M |
| 1-day change | +11.12% | 0.00% |
| YTD return | +29.88% | -43.19% |
| 1-year return | +52.56% | -44.87% |
| 5-year return | -82.76% | -97.86% |
| EPS (TTM) | $-0.68 | $-2.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $12.29M | $800.00K |
| Revenue growth (YoY) | -15.03% | -77.14% |
| Net income (latest FY) | $53.38M | $-45.35M |
| Gross margin | 53.66% | — |
| Operating margin | -218.91% | -6056.38% |
| Net margin | 434.23% | -5668.63% |
| 52-week high | $1.39 | $7.60 |
| 52-week low | $0.50 | $3.00 |
| Distance from 52-week high | -35.01% | -48.42% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +455.49% | +359.18% |
| Average volume | 185.17K | 15.86K |
| Shares outstanding | 44.40M | 12.46M |
| Employees | 25 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ELUT has outperformed IMA by 97.4 percentage points over the past year.
- Elutia is more profitable, keeping 434.2 cents of every revenue dollar as net income versus -5668.6 cents for ImageneBio.
- Elutia grew revenue faster in its latest fiscal year (-15.03% vs -77.14%).
About Elutia
ELUT stock →Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 25 employees
About ImageneBio
IMA stock →ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
ELUT vs IMA FAQ
Which is bigger, Elutia or ImageneBio?
ImageneBio (IMA) is larger, with a market capitalization of $48.83M compared with $39.96M for Elutia (ELUT).
Which stock has performed better over the past year, ELUT or IMA?
ELUT returned +52.56% over the past 12 months, compared with -44.87% for IMA (price return, excluding dividends). Past performance does not predict future results.
Are Elutia and ImageneBio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.